文献检索文档翻译深度研究
Suppr Zotero 插件Zotero 插件
邀请有礼套餐&价格历史记录

新学期,新优惠

限时优惠:9月1日-9月22日

30天高级会员仅需29元

1天体验卡首发特惠仅需5.99元

了解详情
不再提醒
插件&应用
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
高级版
套餐订阅购买积分包
AI 工具
文献检索文档翻译深度研究
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2025

从测序到验证:基于二代测序技术对甲状腺乳头状癌血浆微小RNA的探索

From sequencing to validation: NGS-based exploration of plasma miRNA in papillary thyroid carcinoma.

作者信息

Cui WangPeng, Xuan Tao, Liao Tian, Wang Yu

机构信息

Department of Head and Neck Surgery, Fudan University Shanghai Cancer Center, Fudan University, Shanghai, China.

Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China.

出版信息

Front Oncol. 2024 Aug 7;14:1410110. doi: 10.3389/fonc.2024.1410110. eCollection 2024.


DOI:10.3389/fonc.2024.1410110
PMID:39169938
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC11335555/
Abstract

OBJECTIVE: A non-invasive method using plasma microRNAs provides new insights into thyroid cancer diagnosis. The objective of this study was to discover potential circulating biomarkers of papillary thyroid carcinoma (PTC) through the analysis of plasma miRNAs using next-generation sequencing (NGS). METHODS: Plasma miRNAs were isolated from peripheral blood samples collected from healthy individuals, patients diagnosed with PTC, and those with benign thyroid nodules. The Illumina NovaSeq 6000 platform was employed to establish the miRNA expression profiles. Candidate miRNAs for diagnostic purposes were identified utilizing the Random Forest (RF) algorithm. The selected miRNAs were subsequently validated in an independent validation set using RT-qPCR. RESULTS: NGS results revealed consistent plasma miRNA expression patterns among healthy individuals and patients with benign thyroid nodules in the discovery set (6 healthy cases, 17 benign cases), while differing significantly from those observed in the PTC group (17 PTC cases). Seven miRNAs exhibiting significant expression differences were identified and utilized to construct an RF classifier. Receiver operating characteristic (ROC) analysis for PTC diagnosis, and the area under the curve (AUC) was 0.978. Subsequent KEGG and GO analyses of the target genes associated with these 7 miRNAs highlighted pathways relevant to tumors and the cell cycle. Independent validation through RT-qPCR in a separate cohort (15 CONTROL, 15 PTC groups) underscored hsa-miR-301a-3p and hsa-miR-195-5p as promising candidates for PTC diagnosis. CONCLUSION: In conclusion, our study established a seven-miRNA panel in plasma by Random Forest algorithm with significant performance in discriminating PTC from healthy or benign group. , in plasma have potential for further study in the diagnosis of PTC in Asian ethnic.

摘要

目的:一种使用血浆微小RNA的非侵入性方法为甲状腺癌诊断提供了新的见解。本研究的目的是通过使用下一代测序(NGS)分析血浆微小RNA,发现甲状腺乳头状癌(PTC)潜在的循环生物标志物。 方法:从健康个体、被诊断为PTC的患者以及患有良性甲状腺结节的患者采集的外周血样本中分离血浆微小RNA。采用Illumina NovaSeq 6000平台建立微小RNA表达谱。利用随机森林(RF)算法识别用于诊断目的的候选微小RNA。随后在独立验证集中使用RT-qPCR对所选微小RNA进行验证。 结果:NGS结果显示,在发现集(6例健康病例,17例良性病例)中,健康个体和患有良性甲状腺结节的患者血浆微小RNA表达模式一致,而与PTC组(17例PTC病例)中观察到的模式有显著差异。识别出7种表现出显著表达差异的微小RNA,并用于构建RF分类器。对PTC诊断进行受试者操作特征(ROC)分析,曲线下面积(AUC)为0.978。随后对与这7种微小RNA相关的靶基因进行KEGG和GO分析,突出了与肿瘤和细胞周期相关的途径。在另一个队列(15例对照,15例PTC组)中通过RT-qPCR进行的独立验证强调了hsa-miR-301a-3p和hsa-miR-195-5p作为PTC诊断的有前景的候选者。 结论:总之,我们的研究通过随机森林算法在血浆中建立了一个七微小RNA面板,在区分PTC与健康或良性组方面具有显著性能。血浆中的 在亚洲人种PTC诊断中具有进一步研究的潜力。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d5/11335555/43566c7fe9ed/fonc-14-1410110-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d5/11335555/22a1a6b288f9/fonc-14-1410110-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d5/11335555/0a13a6ac7fd4/fonc-14-1410110-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d5/11335555/f50cfd5300f7/fonc-14-1410110-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d5/11335555/57c337497b69/fonc-14-1410110-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d5/11335555/43566c7fe9ed/fonc-14-1410110-g005.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d5/11335555/22a1a6b288f9/fonc-14-1410110-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d5/11335555/0a13a6ac7fd4/fonc-14-1410110-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d5/11335555/f50cfd5300f7/fonc-14-1410110-g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d5/11335555/57c337497b69/fonc-14-1410110-g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/59d5/11335555/43566c7fe9ed/fonc-14-1410110-g005.jpg

相似文献

[1]
From sequencing to validation: NGS-based exploration of plasma miRNA in papillary thyroid carcinoma.

Front Oncol. 2024-8-7

[2]
A Panel of Plasma Exosomal miRNAs as Potential Biomarkers for Differential Diagnosis of Thyroid Nodules.

Front Genet. 2020-5-19

[3]
Circulating miR-25-3p and miR-451a May Be Potential Biomarkers for the Diagnosis of Papillary Thyroid Carcinoma.

PLoS One. 2015-7-13

[4]
A three plasma microRNA signature for papillary thyroid carcinoma diagnosis in Chinese patients.

Gene. 2019-1-24

[5]
Identification of exosomal miRNA biomarkers for diagnosis of papillary thyroid cancer by small RNA sequencing.

Eur J Endocrinol. 2020-1

[6]
Circulating microRNA124-3p, microRNA9-3p and microRNA196b-5p may be potential signatures for differential diagnosis of thyroid nodules.

Oncotarget. 2016-12-20

[7]
A three-microRNA panel in serum as novel biomarker for papillary thyroid carcinoma diagnosis.

Chin Med J (Engl). 2020-11-5

[8]
Circulating microRNA profiles as potential biomarkers for diagnosis of papillary thyroid carcinoma.

J Clin Endocrinol Metab. 2012-4-3

[9]
Exosomal miRNAs are potential diagnostic biomarkers between malignant and benign thyroid nodules based on next-generation sequencing.

Carcinogenesis. 2020-3-13

[10]
Altered Serum MicroRNA Profile May Serve as an Auxiliary Tool for Discriminating Aggressive Thyroid Carcinoma from Nonaggressive Thyroid Cancer and Benign Thyroid Nodules.

Dis Markers. 2019-9-16

引用本文的文献

[1]
Clinical implications of miR-195 in cancer: mechanisms, potential applications, and therapeutic strategies.

J Cancer Res Clin Oncol. 2025-4-22

[2]
The Application of microRNAs in Papillary Thyroid Cancer: A Bibliometric and Visualized Analysis.

Int J Gen Med. 2024-10-15

本文引用的文献

[1]
Hsa-miR-301a-3p inhibited the killing effect of natural killer cells on non-small cell lung cancer cells by regulating RUNX3.

Cancer Biomark. 2023

[2]
Circadian rhythm-related genes index: A predictor for HNSCC prognosis, immunotherapy efficacy, and chemosensitivity.

Front Immunol. 2023

[3]
Exploring the role of sphingolipid-related genes in clinical outcomes of breast cancer.

Front Immunol. 2023

[4]
Identification of novel miRNAs potentially involved in the pathogenesis of adult T-cell leukemia/lymphoma using WGCNA followed by RT-qPCR test of hub genes.

Infect Agent Cancer. 2023-2-25

[5]
Hsa-miR-195-5p Inhibits Autophagy and Gemcitabine Resistance of Lung Adenocarcinoma Cells via E2F7/CEP55.

Biochem Genet. 2023-8

[6]
SIRT1 deacetylates WEE1 and sensitizes cancer cells to WEE1 inhibition.

Nat Chem Biol. 2023-5

[7]
Machine learning to construct sphingolipid metabolism genes signature to characterize the immune landscape and prognosis of patients with uveal melanoma.

Front Endocrinol (Lausanne). 2022

[8]
Identification of Critical miRNAs as Novel Diagnostic Markers for Laryngeal Squamous Cell Carcinoma.

Dis Markers. 2022

[9]
The combined restoration of miR-424-5p and miR-142-3p effectively inhibits MCF-7 breast cancer cell line via modulating apoptosis, proliferation, colony formation, cell cycle and autophagy.

Mol Biol Rep. 2022-9

[10]
Machine learning on thyroid disease: a review.

Front Biosci (Landmark Ed). 2022-3-16

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

推荐工具

医学文档翻译智能文献检索